timolol has been researched along with sdz glc 756 in 3 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 3 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Greiner, B; Laengle, UW; Markstein, R; Roman, D; Schneider, V | 1 |
Court, M; Germann, PG; Laengle, UW; Markstein, R; Nogues, V; Roman, D | 1 |
Laengle, UW; Markstein, R; Pralet, D; Roman, D; Seewald, W | 1 |
3 other study(ies) available for timolol and sdz glc 756
Article | Year |
---|---|
Effects of antiglaucoma drugs timolol and GLC756, a novel dopamine D2 agonist and D1 antagonist, on endotoxin-induced-uveitis in rats.
Topics: Administration, Topical; Adrenergic beta-Antagonists; Animals; Anti-Inflammatory Agents; Aqueous Humor; Betamethasone; Dopamine Agents; Eye Proteins; Glaucoma; Injections, Subcutaneous; Lipopolysaccharides; Quinolines; Rats; Rats, Inbred Lew; Timolol; Tumor Necrosis Factor-alpha; Uveitis | 2005 |
Effects of anti-glaucoma drugs timolol and GLC756, a novel mixed dopamine D2 receptor agonist and D1 receptor antagonist, on endotoxin-induced-uveitis and -arthritis in rats.
Topics: Animals; Arthritis; Glaucoma; Lipopolysaccharides; Quinolines; Rats; Rats, Inbred Lew; Receptors, Dopamine D1; Receptors, Dopamine D2; Timolol; Uveitis | 2005 |
Effect of GLC756, a novel mixed dopamine D1 receptor antagonist and dopamine D2 receptor agonist, on TNF-alpha release in vitro from activated rat mast cells.
Topics: Animals; Antihypertensive Agents; Cell Death; Dose-Response Relationship, Drug; Latanoprost; Mast Cells; Prostaglandins F, Synthetic; Quinolines; Rats; Receptors, Dopamine D1; Receptors, Dopamine D2; Timolol; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha | 2006 |